Analyst Rating Update on bluebird bio (BLUE)

bluebird bio (BLUE) : 12 analysts are covering bluebird bio (BLUE) and their average rating on the stock is 1.5, which is read as a Strong Buy. 9 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels. A total of 3 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

bluebird bio (BLUE) : The highest short term price target forecast on bluebird bio (BLUE) is $117 and the lowest target price is $42. A total of 10 equity analysts are currently covering the company. The average price of all the analysts is $81.6 with a standard deviation of $29.7.

For the current week, the company shares have a recommendation consensus of Buy.


bluebird bio (NASDAQ:BLUE): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $55.11 and $54.50 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $59.63. The buying momentum continued till the end and the stock did not give up its gains. It closed at $59.41, notching a gain of 7.22% for the day. The total traded volume was 1,104,420 . The stock had closed at $55.41 on the previous day.

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Companys products include Lenti-D, LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy), the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States, Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.